GI
GBT

Gradient Investments’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Gradient Investments’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3
Closed – – 1177
2018
Q1 		$0 Hold
3
– – ﹤0.01% 1211
2017
Q4 		$0 Buy
+3
New +$112 ﹤0.01% 1113

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Gradient Investments's GBT Position: Q2 2018 in Review

Gradient Investments sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2018, closing a stake of 3 shares.

Gradient Investments first reported a position in GBT in Q4 2017 and held it in 2 quarters. The position peaked at $0 in Q1 2018. 196 funds tracked by Wall St. Rank hold GBT as of Q2 2018.

  • Gradient Investments reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Gradient Investments sold 3 Global Blood Therapeutics, Inc. shares in Q2 2018.
  • Gradient Investments first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 2 quarters.
  • Gradient Investments's Global Blood Therapeutics, Inc. position peaked at $0 in Q1 2018.
  • 196 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2018.

Based on Gradient Investments's 13F filing for Q2 2018, filed 9 Aug 2018.